Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.

Slavcev, Mary; Spinelli, Allison; Absalon, Elisabeth; Masterson, Tara; Heuck, Christoph; Lam, Annette; De Cock, Erwin

Slavcev, Mary; Spinelli, Allison; Absalon, Elisabeth; Masterson, Tara; Heuck, Christoph; Lam, Annette; De Cock, Erwin.

Afiliación

Slavcev M; Global Market Access, Janssen Global Services, Raritan, NJ, USA.
Spinelli A; Global Medical Affairs, Janssen Global Services, Raritan, NJ, USA.
Absalon E; Real World and Late Phase, Syneos Health Clinical SARL, Paris, France.
Masterson T; Medical Group Oncology, Janssen Research & Development, LLC, Spring House, PA, USA.
Heuck C; Medical Group Oncology, Janssen Research & Development, LLC, Spring House, PA, USA.
Lam A; Global Market Access, Janssen Global Services, Raritan, NJ, USA.
De Cock E; Real World and Late Phase, Syneos Health Clinical Spain SL, Madrid, Spain.

Clinicoecon Outcomes Res ; 13: 465-473, 2021.

Article en En | MEDLINE | ID: mdl-34135605

Palabras clave

daratumumab; subcutaneous; survey; treatment burden

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Clinicoecon Outcomes Res Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google